Prof Robert Orlowski speaks to ecancer about the data featured at ASH 2025 regarding the LINKER-MM4 trial.

The study explores the first BCMA×CD3 bispecific monotherapy for newly diagnosed multiple myeloma, aiming to simplify complex treatment regimens.

Prof Orlowski breaks down the study design, key outcomes, safety findings, and what this means for the future of multiple myeloma treatment.

He says that early data shows rapid, deep responses across all dose levels, including ≥70% VGPR rates and 95% MRD negativity among evaluable patients, with a manageable safety profile.

These promising findings suggest linvoseltamab may become a foundational frontline therapy for both transplant-eligible and transplant-ineligible patients.